Myeloma MRD by Flow Cytometry: Put the Denominator Beside the Negative Result

A sensitivity number needs a denominator

When a flow cytometry report says that measurable residual disease was not detected, the next editorial question should be: how much suitable material was actually examined? A negative result and a validated analytical detection limit answer different questions. Recording both makes a laboratory discussion more useful than attaching a familiar sensitivity number to every specimen.

What the original NGF study established

Flores-Montero and colleagues' 2017 EuroFlow study in Leukemia developed a two-tube, eight-colour next generation flow approach for myeloma MRD. Panel development involved five optimization cycles and bulk lysis to support acquisition of large cell numbers. In 110 follow-up marrow samples from patients in very good partial response or complete response, NGF detected MRD in 52 samples, compared with 37 using conventional eight-colour flow.

The methods distinguish detection from quantification: the authors calculated their limits using at least 20 and 50 aberrant plasma-cell events, respectively, among ten million evaluated events. Their sample-quality assessment also identified reduced marrow-associated populations suggestive of blood contamination. These are features of the evaluated assay and specimens, rather than a sensitivity guarantee transferable to any local workflow.

Three fields worth keeping beside the result

A useful local reporting discussion can start with three separate fields: the assay's validated capability, the evaluable denominator in this specimen, and a statement about specimen adequacy. Keeping these fields separate makes it easier to see when the requested clinical question exceeds the evidence available from the submitted material. The illustration is an original CFCM reporting concept, not a reproduction of the paper's gating strategy.

For a local audit, ask the team to trace one negative report back to its acquisition record. Can another reviewer reconstruct which events contributed to the denominator? Can they find the specimen-quality observations and the laboratory's rule for qualifying an inadequate sample? If the answer depends on an undocumented recollection, improve that record before changing the wording of the report.

Keep the comparison within its study setting

This article uses a historical primary study to explain an analytical reporting question. It does not establish a current universal treatment rule, certify a laboratory's implementation, or demonstrate that another reagent panel has equivalent performance. Contemporary clinical decisions require the relevant clinical context and locally verified procedures.

Daily Learning Pill

Before interpreting a negative MRD label, locate its denominator and adequacy statement. A clear record should let the next reviewer distinguish an assay specification from what this particular specimen supported.

Explore the CFCM clinical cytometry resources and use this three-field discussion in your next reporting audit. This is educational analysis by ChatGPT/Codex, not independent scientific review or clinical validation.